Luis Ortega-Paz, Wilbert Bor, Francesco Franchi, Wout W A van de Broek, Fabiana Rollini, Salvatore Giordano, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Haroutioun Garabedian, Tala Al Saleh, Ekin Uzunoglu, Xuan Zhou, Andrea Rivas, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Madeline K Mahowald, Calvin Y Choi, Martin M Zenni, Fladia Phoenix, Ramzi A Ajjan, Jurrien M Ten Berg, Dominick J Angiolillo
BACKGROUND: Among patients treated with a novel oral anticoagulant (NOAC) undergoing percutaneous coronary intervention (PCI), combination therapy with clopidogrel (i.e., known as dual antithrombotic therapy [DAT]) is the treatment of choice. However, there are concerns for individuals with impaired response to clopidogrel. OBJECTIVES: To assess the pharmacodynamic (PD) effects of clopidogrel vs. low-dose ticagrelor in patients with impaired clopidogrel response assessed by the ABCD-GENE score...
April 1, 2024: JACC. Cardiovascular Interventions